Welcome to Paradigm Therapeutics! Here at Paradigm, our mission is to improve the lives of patients experiencing serious, life-threatening diseases by the discovery, development and delivery of innovative therapies. Our lead therapy, Zorblisa™, is a proprietary topical therapy being developed for the treatment of patients with Epidermolysis Bullosa (EB).

Epidermolysis Bullosa (EB) is a rare genetic connective tissue disorder that typically manifests at birth or early childhood. Disease manifestations of EB include fragile skin that leads to blisters, wounds in the epidermis and dermis, poor wound healing, and skin infections that can be life-threatening. The therapeutic needs of these patients are underserved by the current treatment options available which only offer palliative care.

Zorblisa™ is a therapy that can be administered across the whole body of EB patients to address the disease manifestations of EB including wound healing, wound burden, and infections.